MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $45.75 (17.13% upside)

Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016OppenheimerReiterated RatingOutperform$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016BMO Capital MarketsInitiated CoverageMarket Perform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Wells FargoReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/18/2015Leerink SwannReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015Citigroup Inc.Initiated CoverageNeutral -> Buy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015GuggenheimInitiated CoverageBuy$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q1($0.53)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015Q414($0.10)($0.55)$4.65 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.40)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q2 14($0.27)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2014Q4($0.40)($0.43)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013($0.57)($2.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.87)($0.46)($0.62)
Q2 20162($0.76)($0.57)($0.67)
Q3 20163($0.80)($0.53)($0.65)
Q4 20163($1.38)($0.59)($0.88)
(Data provided by Zacks Investment Research)
Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Five Prime Therapeutics (NASDAQ:FPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
DateHeadline
06/25/16 07:56 AMStock Tracing Lower on the Week Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Engelwood Daily
06/23/16 04:04 AMEarnings Watch: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - iStreetWire
06/22/16 08:44 AMStrong Buy Calls Count For Five Prime Therapeutics, Inc. (NASDAQ:FPRX) At 4 - Investor Newswire
06/20/16 03:55 PMCompany Shares of Five Prime Therapeutics Drops by -8.05% - Trade Calls
06/20/16 01:27 PMETF’s with exposure to Five Prime Therapeutics, Inc. : June 20, 2016 -
06/20/16 10:16 AMFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 05:28 AMFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Current Analyst Ratings - Fiscal Standard
06/06/16 03:57 PMFive Prime Therapeutics (FPRX) Offers Updated Data on FP-1039 Phase 1b in Mesothelioma; Three DLTs Noted - StreetInsider.com
06/06/16 03:57 PMFive Prime Therapeutics (FPRX) Presents Updated FPA144 Phase 1 Data; Safety Findings Seen Similar - StreetInsider.com
06/06/16 08:38 AMFive Prime Therapeutics Presents Updated Data from Phase 1 trial of Single-Agent FPA144 at 2016 ASCO Annual Meeting - [at noodls] - June 6, 2016 Initial data show a 33% confirmed objective response rate, 77% disease control rate, and 12-week progression free survival of 67% in 9 FGFR2b+ gastric cancer patients available for analysis ...
06/06/16 07:24 AMFive Prime Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FPRX-US : June 6, 2016 -
06/06/16 05:11 AMFIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/05/16 04:01 PMPerformance Review for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - HNN
06/04/16 04:03 PMFive Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 ... - GlobeNewswire (press release)
06/04/16 08:48 AMFive Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting - [at noodls] - June 4, 2016 Objective response rate of 39% and disease control rate of 100% in patients at or below the maximum tolerated dose level; progression free survival of 6.8 months, though data are still maturing ...
06/02/16 08:45 AMFive Prime Therapeutics to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - June 1, 2016 SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative ...
06/01/16 10:23 PMFive Prime Therapeutics (FPRX) Names Dr. Robert Sikorski as CMO - StreetInsider.com - Five Prime Therapeutics (FPRX) Names Dr. Robert Sikorski as CMOStreetInsider.comFive Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Robert Sikorski, M.D., Ph.D., to chief ...and more »
06/01/16 04:20 PMFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Stock Update & Estimates - Stock Tick Tock - Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to post earnings of $-0.72 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/01/16 03:15 PMFive Prime Therapeutics Appoints Dr. Robert Sikorski as Chief Medical Officer - [at noodls] - June 1, 2016 SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative ...
05/31/16 08:50 AMStock Review and Earnings Check on Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - HNN - Stock Review and Earnings Check on Five Prime Therapeutics, Inc. (NASDAQ:FPRX)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report quarterly EPS of $-0.72. The company's next earnings report is expected to be ...and more »
05/30/16 09:43 PMTarget Check and Stock Performance Recap Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - HNN - Target Check and Stock Performance Recap Five Prime Therapeutics, Inc. (NASDAQ:FPRX)HNNTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Five Prime Therapeutics, Inc.and more »
05/30/16 09:43 PMFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Daily Sentiment Score Of 0.369 - RealistInvestor.com - Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Daily Sentiment Score Of 0.369RealistInvestor.comFive Prime Therapeutics, Inc. (NASDAQ:FPRX) has a daily sentiment score of 0.369. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web.and more »
05/29/16 11:14 PMFive Prime Therapeutics Inc (FPRX) Receives “Buy” Rating from Credit Suisse - Let Me Know About This - Five Prime Therapeutics Inc (FPRX) Receives “Buy” Rating from Credit SuisseLet Me Know About ThisFive Prime Therapeutics Inc (NASDAQ:FPRX)'s stock had its “buy” rating reaffirmed by stock analysts at Credit Suisse in a report issued on Sunday. Other hedge funds recently bought and sold shares of the company. Legal & General Group Plc raised its ...Volatile post-earnings mover: Five Prime Therapeutics, Inc. (NASDAQ:FPRX)CWRU ObserverFive Prime Therapeutics, Inc. (NASDAQ:FPRX) EPS Estimate At $-0.78Equities FocusIs it Time to Cash in Profits on Five Prime Therapeutics, Inc. (NASDAQ:FPRX)Franklin IndependentRisers & Fallers -HNN -News Tribuneall 10 news articles »
05/28/16 11:18 PMFive Prime Therapeutics : How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics - ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at: http://www.activewallst.com On Wednesday, shares in Massachusetts headquartered biopharma Company, Radius Health Inc., ended the session ...
05/27/16 09:33 AMFive Prime Therapeutics Inc on Focus After Raising In Today's Session - Wall Street Hints and News - Five Prime Therapeutics Inc on Focus After Raising In Today's SessionWall Street Hints and NewsThe stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) is a huge mover today! The stock increased 2.68% or $1.17 during the last trading session, hitting $44.9. About 361,394 shares traded hands. Five Prime Therapeutics Inc (NASDAQ:FPRX) has risen ...
05/26/16 09:47 AMTraders Observable Stocks: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) , Prestige Brand Holdings, Inc. (NYSE:PBH) - Street Updates - Traders Observable Stocks: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) , Prestige Brand Holdings, Inc. (NYSE:PBH)Street UpdatesOn 5/25/2016, shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) fell -1.38% in trading session and finally closed at $43.73. The company most recent volume stood at 378.35 thousand shares as compared to its average volume of 627.82 thousand ...Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Latest Broker ViewsRisers & FallersTop Earnings to Watch for: Five Prime Therapeutics (NASDAQ:FPRX)iStreetWireall 3 news articles »
05/25/16 11:23 PMStock Rating Review for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Wall Street Hints and News - Stock Rating Review for Five Prime Therapeutics, Inc. (NASDAQ:FPRX)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.4 on shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Covering ...and more »
05/23/16 11:24 PMTarget Check and Stock Performance Recap Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Wall Street Hints and News - Target Check and Stock Performance Recap Five Prime Therapeutics, Inc. (NASDAQ:FPRX)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Five Prime Therapeutics, Inc.
05/23/16 11:24 PMTrader's Watch List: Five Prime Therapeutics Inc (NASDAQ:FPRX), Lending Club Corp (NYSE:LC) - NYSE Journal (press release) - Trader's Watch List: Five Prime Therapeutics Inc (NASDAQ:FPRX), Lending Club Corp (NYSE:LC)NYSE Journal (press release)Five Prime Therapeutics Inc (NASDAQ:FPRX) belongs to Healthcare sector and Biotechnology industry. FPRX stock opened its current trade at $42.66 and now is floating in a range of $42.66 to $43.82, trading at $43.46. FPRX stock gain 0.63% in total of ...
05/22/16 10:48 PMFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Broker Price Targets For The Coming Week - Share Trading News - Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX). The latest reports which are currently in issue on Sunday 22nd of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/20/16 10:49 AMETF’s with exposure to Five Prime Therapeutics, Inc. : May 20, 2016 -
05/20/16 09:59 AMTraders Observable Stocks: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) , Sucampo Pharmaceuticals, Inc. (NASDAQ ... - Street Updates - Traders Observable Stocks: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) , Sucampo Pharmaceuticals, Inc. (NASDAQ ...Street UpdatesFive Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, recently reported that updated data from the ongoing clinical trials of FPA144 and ...and more »
05/20/16 05:11 AMFIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement -
05/19/16 09:41 AMFive Prime Therapeutics (FPRX) Says Updated Data on FPA144 and FP-1039 to be Presented at ASCO - Get your Free Trial here. Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that updated data from the ongoing clinical ...
05/18/16 11:23 PMRevenue Update on Five Prime Therapeutics Inc(NASDAQ:FPRX) - Trade Calls - Revenue Update on Five Prime Therapeutics Inc(NASDAQ:FPRX)Trade CallsFive Prime Therapeutics Inc(NASDAQ:FPRX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 5, 2016. Company reported revenue of $6.52M. Analysts estimated a revenue of $5.26M. Earnings per ...
05/18/16 06:14 PMFive Prime Therapeutics (FPRX) Says Updated Data on FPA144 and FP-1039 to be Presented at ASCO - StreetInsider.com - Five Prime Therapeutics (FPRX) Says Updated Data on FPA144 and FP-1039 to be Presented at ASCOStreetInsider.comFive Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that updated data from the ongoing clinical trials of FPA144 and ...Five Prime Therapeutics Inc.: Five Prime Therapeutics Announces Updated Clinical Data on FPA144 and FP-1039 to ...The Wall Street Transcriptall 2 news articles »
05/18/16 04:11 PM5:11 pm Five Prime Therapeutics to present updated data from the ongoing clinical trials of FPA144 and FP-1039 at ASCO -
05/18/16 04:00 PMFive Prime Therapeutics Announces Updated Clinical Data on FPA144 and FP-1039 to be Presented during 2016 ASCO Annual Meeting - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., May 18, 2016-- Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, ...
05/18/16 10:45 AMFive Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 06:03 PMFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Quarterly EPS Projection At $-0.78 - Investor Newswire - Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Quarterly EPS Projection At $-0.78Investor NewswireA week earlier, the EPS projection was $-0.78 while 30-days ago it was $-0.78. This target was set at $-0.78 60 days ago and it was $-0.78 90 days earlier. From a week ago, the change in estimates is 0%. EPS was revised 0 times up and 0 down in last ...and more »
05/17/16 10:15 AMToday's Stocks: Five Prime Therapeutics (NASDAQ:FPRX), Unico American (NASDAQ:UNAM), Agnico Eagle Mines ... - KC Register - Today's Stocks: Five Prime Therapeutics (NASDAQ:FPRX), Unico American (NASDAQ:UNAM), Agnico Eagle Mines ...KC RegisterOn May 12, Five Prime Therapeutics, Inc. (NASDAQ:FPRX) announced the advancement of FPA008 into the Phase 2 dose expansion portion of the ongoing Phase 1/2 trial in PVNS. Five Prime initiated patient dosing in this Phase 1/2 clinical trial of FPA008 in ...
05/17/16 10:15 AMShare Recap and Earnings Focus on Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Wall Street Hints and News - Share Recap and Earnings Focus on Five Prime Therapeutics, Inc. (NASDAQ:FPRX)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Five Prime Therapeutics, Inc.and more »
05/12/16 06:38 PMEarnings Analysis to Watch: Five Prime Therapeutics (FPRX) - News Oracle - Earnings Analysis to Watch: Five Prime Therapeutics (FPRX)News OracleLast Trade: The Company fell -1.27% and finished at $41.17. The daily volume was measured at 411,769.00 shares. The 52-week high of the share price is $50.11 and the 52-week low is $14.70. The company has a market cap of $1.13 Billion. The stock has ...and more »
05/12/16 06:38 PMFive Prime Therapeutics (FPRX) Announced Advancement of FPA008 into Dose-Expansion Phase 2 - StreetInsider.com - Five Prime Therapeutics (FPRX) Announced Advancement of FPA008 into Dose-Expansion Phase 2StreetInsider.comFive Prime Therapeutics, Inc. (Nasdaq: FPRX) announced the advancement of FPA008 into the Phase 2 dose expansion portion of the ongoing Phase 1/2 trial in PVNS. “We are very pleased to progress to the Phase 2 portion of this trial evaluating FPA008 as ...Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular ...GlobeNewswire (press release)all 1 news articles »
05/12/16 08:17 AMFive Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis (PVNS) - [at noodls] - May 12, 2016 SOUTH SAN FRANCISCO, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) a clinical-stage biotechnology company focused on discovering and developing novel ...
05/12/16 05:02 AMFive Prime Therapeutics (FPRX) Is Today's Perilous Reversal Stock - See the FREE profile for FPRX NOW at Trade-Ideas More details on FPRX: Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease ...
05/10/16 04:44 AMFive Prime Therapeutics Inc (FPRX) Jumps 6.7% on May 09 - Equities.com - Five Prime Therapeutics Inc (FPRX) Jumps 6.7% on May 09Equities.comFive Prime Therapeutics Inc (FPRX) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 6.7% to $43.02, representing a gain of $2.7 per share. Some 745,654 shares traded hands on 7,701 trades, compared with an ...and more »
05/09/16 06:25 PMAnalytical Report of the Stock: Five Prime Therapeutics Inc (FPRX) - News Oracle - News OracleAnalytical Report of the Stock: Five Prime Therapeutics Inc (FPRX)News OracleLast Trade: The Company fell -3.75% and finished at $40.32. The daily volume was measured at 1.06 million shares. The 52-week high of the share price is $50.11 and the 52-week low is $14.70. The company has a market cap of $1.08 billion. The stock has ...and more »
05/09/16 07:32 AMFive Prime Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FPRX-US : May 9, 2016 -
05/07/16 11:08 PMTwo Biotech stocks to Watch: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) , IDEXX Laboratories, Inc. (NASDAQ:IDXX) - Is stories - Is storiesTwo Biotech stocks to Watch: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) , IDEXX Laboratories, Inc. (NASDAQ:IDXX)Is storiesFive Prime Therapeutics, Inc. (NASDAQ:FPRX) decreased -3.75% to $40.32 while traded 1.06 million shares on 5/6/2016. The stock price negotiated for value between $37.69 to $41.74 in recent trading session. During the past 52 weeks, the stock's price ...Five Prime Therapeutics Drops 5% Though Q1 Beats Estimates (NASDAQ:FPRX)Sonoran Weekly ReviewFive Prime Therapeutics Inc Declines Again; Strong Momentum for SellersFranklin IndependentFive Prime Therapeutics' (FPRX) CEO Rusty Williams on Q1 2016 Results - Earnings Call TranscriptSeeking Alphaall 5 news articles »
About Five Prime Therapeutics

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company's product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $39.06
  • 50 Day Moving Average: $42.28
  • 200 Day Moving Average: $39.35
  • P/E Ratio: 4.32
  • P/E Growth: 0.53
  • Market Cap: $1.03B
  • Current Quarter EPS Consensus Estimate: $-2.64 EPS
Additional Links:
Five Prime Therapeutics (NASDAQ:FPRX) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha